North East and North Cumbria
ICS Formulary
 
back
6 Endocrine system
06-06-01 Calcitonin and parathyroid hormone

Calcitonin 400units in 2ml
Formulary

Red View adult BNF  View SPC online  View childrens BNF
Teriparatide 250microgram in 1ml prefilled pen Biosimilar brands - Movymia®,Terrosa® & Teva
Formulary

  • Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE.**All new patients**

  • Approved for the treatment of osteoporosis in males and juveniles in line with NHSE Commissioning Policy
Link  Biosimilar teriparatide for the treatment of osteoporosis in postmenopausal women as per NICE TA161.
Link  Clinical Commissioning Policy: Teriparatide for osteoporosis (in male adults)
Link  NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Link  NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Red View adult BNF  View SPC online  View childrens BNF
Teriparatide 250microgram in 1ml prefilled pen Forsteo®
Formulary

  • Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE. **Exisiting patients only**

  • Approved for the treatment of osteoporosis in males and juveniles in line with NHSE Commissioning Policy
Link  Clinical Commissioning Policy: Teriparatide for osteoporosis (in male adults)
Link  NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Link  NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Red View adult BNF  View SPC online  View childrens BNF